Sign In
Buy CRBU
$1.80
-0.125 (-6.49%)
At Close: Jul 13, 2026
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
10:41am, Thursday, 09'th Jul 2026
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
08:00am, Monday, 29'th Jun 2026
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
08:01am, Thursday, 11'th Jun 2026
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient admi
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
08:00am, Thursday, 11'th Jun 2026
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
06:06am, Tuesday, 09'th Jun 2026
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
04:52pm, Friday, 05'th Jun 2026
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
04:05pm, Wednesday, 27'th May 2026
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
08:10pm, Friday, 15'th May 2026
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
04:05pm, Wednesday, 13'th May 2026
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's ma
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts hav
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.43 per share a year ago.
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Thursday, 07'th May 2026
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMoufl
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
04:05pm, Tuesday, 05'th May 2026
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
Three Best Genomics Stocks for Your Portfolio in 2026
11:20am, Monday, 13'th Apr 2026
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-na
